Merck bets on Asia growth with $338m Korea investment
Only one outlet has reported this so far: treat it as unconfirmed.
German science and technology giant Merck is betting big on Korea as a manufacturing hub for Asia's booming biopharmaceutical industry, investing 300 million euros ($337 million) in a new production center in Daejeon. The facility, Merck's largest life science investment in Asia-Pacific to date, is central to its "in-region, for-region" strategy, aimed at reducing reliance on manufacturing sites in the US and Europe while tapping Asia's rapidly expanding biotech market. "Asia, including Korea an
How sure are we
Only one outlet so far: treat it as unconfirmed. That doesn’t make it false; it may be new, or an exclusive.
Who reported it
No verification data yet
Checks run automatically as new sources are ingested.
Score bands
What moves the score
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
Very high · How we score this